Relationship Between Metabolic Tumor Volume and Rituximab Pharmacokinetic Parameters in Non-Hodgkin’s Lymphoma
نویسندگان
چکیده
منابع مشابه
Non-Hodgkins Lymphoma presenting as Garcin’s Syndrome
An 80 year old man presented with a twelve month history of progressive multiple unilateral cranial nerve palsies. A gadolinium enhanced MRI scan of his head and neck was performed. This showed an extra-axial enhancing lesion, which enveloped the hemi-mandible at the level of the left inferior alveolar nerve, and a dumbbell shaped lesion within the cerebellopontine angle. An incisional biopsy w...
متن کاملSmall B cell Non-Hodgkins Lymphoma in Pakistan.
OBJECTIVE To study the pattern of small B cell lymphomas in Pakistan. METHODS This descriptive study was carried out at the Aga Khan University Hospital pathology department including 1721 cases of Non-Hodgkins Lymphoma (NHL) diagnosed during a period of five years (1998-2002) and classified according to REAL/WHO classification. The antibodies used included Leukocyte Common Antigen (LCA), Pan...
متن کاملMotor neuron disease and its association with non-Hodgkins lymphoma.
M otor neuron disease (MND) is a neurodegenerative disorder characterized by muscle atrophy, brisk reflexes, spasticity, fasciculation, and atrophy. The onset of the disease is generally insidious. The pathological process may involve the motor cortex, the spinal cord, and the brainstem. 1 Only upper or only lower motor neurons may be affected. The disease may or may not be seen with neoplasms,...
متن کاملRituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study
word count: 249/250 words Text word count: 3461/4000 words Number of tables and figures: 6 Reference count: 41 For personal use only. on March 3, 2017. by guest www.bloodjournal.org From Ac ce pte d m an us cri pt
متن کاملRituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
High variability in patient outcome after rituximab-based treatment is partly explained by rituximab concentrations, and pharmacokinetic (PK) variability could be influenced by tumor burden. We aimed at quantifying the influence of baseline total metabolic tumor volume (TMTV0) on rituximab PK and of TMTV0 and rituximab exposure on outcome in patients with diffuse large B-cell lymphoma (DLBCL). ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2014
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v124.21.3644.3644